Navigation Links
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life

ielded through an online panel that closely reflects the U.S. adult population overall. Physicians were recruited from a list of all board certified gastroenterologists in the U.S. Assuming no sample bias, the margin of error for the sample of 451 UC patients is +/- 5 percent; assuming no sample bias, the margin of error for a sample of 300 (the other surveys) is +/- 6 percent.

For more information about the survey, visit http://www.UCNORMAL.com. For more information on ulcerative colitis, visit http://www.managinguc.com.

About UC

UC is a type of inflammatory bowel disease that produces chronic inflammation and sores or ulcers along the inside of the large intestine. Symptoms may include severe abdominal pain and cramping, frequent and sometimes uncontrollable bloody diarrhea, fatigue and weight loss. This chronic autoimmune disease is typically first diagnosed in people between the ages of 15 to 30 and is estimated to affect nearly 700,000 Americans. According to the National Institutes of Health, about five percent of people with UC will develop colon cancer.

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydroph
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
3. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
4. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
5. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
6. New Survey Finds Troubling Data on American Asthma Sufferers
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
11. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation ... to support older adults suffering from the severe ... AARP and its members are committed to helping those ... AARP and AARP Foundation will match dollar-for-dollar contributions up ... aid. The matching program will be administered through AARP ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, ... the Office of Fair Trading (OFT) approval condition to the ... ViroPharma Incorporated (NASDAQ: VPHM).   As a result ... OFT approval, and Shire expects to complete the tender offer ... subject to the satisfaction of all of the remaining conditions ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 2011 PDI, Inc. (Nasdaq: PDII ), a ... companies, today announced the extension of a contract sales engagement ... began April 1 and will run for the balance of ... PDI of approximately $23 million. Under the program, ...
... April 4, 2011 VIVUS, Inc. (Nasdaq: VVUS ... the investigational drug QNEXA® for two years showed reductions in ... as improvements in lipid levels following significant reductions in weight ... two years. The data – additional results ...
Cached Medicine Technology:PDI Announces Contract Extension With Revenue Value of Approximately $23 Million 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:4/14/2014)... the scientific marvels of the 20th century, is currently ... bacterial infections. But scientists at the University of South ... its combat effectiveness, even against so-called "superbugs." , Bacteria ... penicillin family of drugs since their first wide-scale use ... infection, brought about by the bacterium Staphylococcus aureus ...
(Date:4/14/2014)... information on colorectal cancer is too difficult for most ... risks to and concerns of patients, a study by ... review of a dozen popular websites, most of the ... written beyond the recommended sixth-grade reading level, while content ... well as the barriers to and benefits of screening, ...
(Date:4/14/2014)... SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced ... antibody prevents the destruction of human red blood ... a type of autoimmune hemolytic anemia (AIHA). The ... protease C1s, prevents complement activation induced by cold ... the journal Blood earlier this month. ...
(Date:4/14/2014)... Frank Porter Graham Child Development Institute have released ... program to prepare four-year-olds for success in kindergarten. ... Pre-K show significant gains across all areas of ... even greater rate during their participation in NC ... senior scientist Ellen Peisner-Feinberg, who leads the FPG ...
(Date:4/14/2014)... about health that aren,t based on medical evidence are ... research suggests. , In the Ohio State University study, ... as "irrational health beliefs" on a standard measure of ... a prescribed cardiac rehab program. , Among the ... flu vaccine or believing, based on family history alone, ...
Breaking Medicine News(10 mins):Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... Kashmir University Wednesday suspended construction of a guesthouse inside the ... following student protests . ,Vice Chancellor Abdul Wahid ... campus here. ,Hundreds of students had launched an ... chinar trees being felled to make way for the construction. ...
... peoples sleep. Some are light sleepers, whereas others sleep ... their time . ,Such sleeping pattern ... circumstances, habits, and other non-biological factors. But now a ... and assistant director of the Sleep and Performance Research ...
... The international HIV and AIDS charity AVERT is today launching ... end to the 380,000 child AIDS deaths and half ... year. ,At this year's G8 summit in Germany, the ... chance to stop child AIDS deaths by committingspecific funds for ...
... breast Cancer treatment comes in the form of Intraoperative ... radiation during surgery . Thus the patient can avoid ... the Princess Margaret Hospital team combined the expertise of ... and nurses to perform its first procedure. It marked ...
... today seems to be disintegrating at an alarming rate. Studies ... one in ten children now has a mental health disorder ... More than a million children have mental health problems, a ... conduct disorders have become twice as common since the 1930s ...
... The Canadian Food Inspection Agency has issued a warning to ... Alberta, Ontario, Quebec and Nova Scotia as it could ... the product has been done by Les Aliments G. Dion. ... the market. ,Salmonella contaminated food does not appear ...
Cached Medicine News:Health News:Individual Differences in Sleep Structure are Biologically Determined 2Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Intraoperative Radiation Therapy a New Step in Breast Cancer Treatment 2Health News:Mental Health of Children on the Decline 2
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: